β-hydroxybutyrate supplementation boosts the tumor-killing potential of CAR T cells.
Level 5 - mechanism / opinion, no new human data
Commentary discussing a primary research study without reporting new primary empirical data
PubMed 41986177 · doi:10.1016/j.molmed.2026.04.001
What was done
This commentary summarizes and discusses a study by Liu et al. published in Cell evaluating the effect of β-hydroxybutyrate as a metabolic adjuvant for chimeric antigen receptor (CAR) T-cell therapy.
What was found
The abstract reports no numerical data. It notes that β-hydroxybutyrate fuels the tricarboxylic acid (TCA) cycle and alters transcriptional and epigenetic programs, which improves CAR T-cell proliferation, persistence, and tumor clearance.
Why it matters
Supplementing CAR T-cell protocols with ketone bodies could provide an accessible metabolic strategy to bolster adoptive cell therapy against tumors.
Limits
The publication is a short commentary lacking original empirical data, quantitative results, sample sizes, or clinical trial evidence. All conclusions rely entirely on the referenced study.
Cited by
- supports Beta-hydroxybutyrate plays a significant role in expanding CAR T-cells.
- supports Moffitt Cancer Center is investigating the combination of CAR T-cell therapy and ketone metabolic therapy.